no metadatahttps://benchmarkantibodies.com/product/human-cytomegalovirus-igg-lateral-flow-dipstick-kit-5572/
Skip to content

Human Cytomegalovirus IgG Lateral flow dipstick kit 5572

$487.00

Summary

  • Mikrogen diagnostik lateral flow device (dipstick) for research use (RUO)
  • Human Cytomegalovirus IgG Lateral flow dipstick kit 5572
  • Suitable for IgG detection
  • Ready-to-use
  • 20 tests
SKU: 5572 Category: Tags: , ,
Weight 1 lbs
Dimensions 9 × 5 × 2 in
target

Human Cytomegalovirus IgG

species reactivity

Human Cytomegalovirus

applications

Lateral flow (dipstick)

assay type

Indirect & qualitative

available sizes

2x 20 test kits

Human Cytomegalovirus IgG Lateral flow dipstick kit 5572

kit
Assay type
Sandwich assay, lateral flow (dipstick)
Research area
Infectious Disease
Sample type
Serum, plasma, whole blood
Components
10X Wash Buffer 100 mL
TMB Substrate 40 mL
Milk Powder 5 g
Instructions for Use 1 Each
Evaluation Form 1 Each
Test Strips 2 kits of [2 Vials x 10 Each]
Anti-Human IgG Conjugate 500 ?L
Positive Control 140 ?L
Negative Control 140 ?L
Storage
Store at 2-8°C.
Additional information

Mikrogen recomLine CMV tests are serological, qualitative in vitro line immunoassays based on recombinantly produced antigens. The test is used as a confirmatory test of positive and inconclusive screening results. The low predictive value of a positive CMV IgM detection, due to persistent IgM or recurrent infection, makes reliable diagnosis of CMV infection particularly difficult. Using the recomLine CMV, IgG, IgM as well as the avidity of IgG antibodies can be determined. Phase-specific antigens and avidity antigens (patented by MIKROGEN on the Immuno-Line Assay) allow detection of antibodies in all phases of infection. In addition to viral load, the recomLine CMV can be used in pregnancy diagnostics as well as in preoperative diagnostics in transplant patients to detect CMV infection and to determine the time of infection.

The recomLine CMV tests provide a clear answer to the question of what effects the present infection may have on the health status of the individual patient and thus support an optimal therapy decision.

Advantages
  • Highly reliable patient management through the use of phase-specific antigens that characterize the time of infection.
  • Reliable detection of pregnancy-related CMV infections.
  • Simple and clear interpretation due to easy-to-read banding.
  • Partial and full automation, software-based evaluation (recomScan), and integration with laboratory information system possible.
  • Highest sensitivity and specificity through the use of recombinant antigens:
Bands
Antigen Reading Frame/Protein Natural Function Size [kDA]
IE 1 UL 123 / IE 1/1 Non-structural protein, immediate early protein 53
CM2 UL44, UL57 / p52 (DBP) Non-structural protein 45
p150 UL32 / pp150 Tegument protein 50
p65 UL 83 / pp65 Tegument protein 31
gB 1 UL 55 / gB Membrane glycoprotein gB 25
gB 2 UL 55 / gB M
target relevance
Organism
Cytomegalovirus
Structure and strains
Cytomegalovirus (CMV) is a genus of viruses in the order Herpesvirales, in the family Herpesviridae, in the subfamily Betaherpesvirinae. Humans and other primates serve as natural hosts. The 11 species in this genus include human betaherpesvirus 5 (HCMV, human cytomegalovirus, HHV-5), which is the species that infects humans. Diseases associated with HHV-5 include mononucleosis and pneumonia, and congenital CMV in infants can lead to deafness and ambulatory problems.

In the medical literature, most mentions of CMV without further specification refer implicitly to human CMV. Human CMV is the most studied of all cytomegaloviruses.
Disease
Cytomegalovirus (CMV) is a human pathogenic DNA virus belonging to the herpes virus group. Primary infection may result from contact with saliva, genital secretions, urine and breast milk of infected persons, as well as from transfusions or transplantations.

Primary infections usually remain asymptomatic. Clinical manifestations vary considerably depending on age and immunocompetence ranging from localized infections to generalized diseases. Significant clinical diseases or death may follow infection of immunocompromized individuals. Reactivation in immunocompetent adults is usually asymptomatic but accompanied by virus secretion. In immunocompromized patients reactivation of CMV infections may result in clinically severe diseases. CMV infection is a major cause of complications in iatrogenic immunsuppression after organ transplantation and in HIV infected persons. CMV is the most important causative agent of congenital and postnatal infections. Primary infections as well as reactivations during pregnancy may result in fetopathy. The risk of fetal damage is higher in cases of primary infections than during reactivations.
Detection and diagnosis
The diagnosis of CMV infections is performed on the basis of clinical symptoms and medical examinations. For serological diagnosis immunoglobulin specific IgM and IgG ELISA and, when necessary, tests for avidity determination are recommended.

Data

Publications

Publications

pmid title authors citation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
5572 protocol

Documents

#
Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information.